CEO Sofia Heigis in an interview with Biostock

Oncopeptides is in an expansive phase with continued growth for Pepaxti in the European market and progress in its international ventures. In an interview with BioStock, CEO Sofia Heigis talks about the company’s long-term vision, commercial development, and ongoing negotiations in Japan. She also comments on the current rights issue and explains why Oncopeptides considers itself an attractive investment right now.

Watch the interview with CEO Sofia Heigis here (the interview is in Swedish)